• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Syngene

    PCI Pharma Services

    Emergent BioSolutions

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Syngene

    Emergent BioSolutions

    Reed-Lane

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    2019 Trends & Predictions

    Looking to the year ahead we discuss six key trends that will shape the industry.

    2019 Trends & Predictions
    Related CONTENT
    • Trial Runners
    • Mogene
    • SGS Life Sciences
    • Implementing AI in Drug Discovery
    • Quanticate Appoints SVP of Project Delivery
    David Hukin and Thomas Underwood, QVigilance and Quanticate03.06.19
    2019 is set to be an important year for the pharmaceutical industry. Implementation of new regulations, such as the EU’s Clinical Trials Regulation and Falsified Medicines Directive, Brexit and the emergence of revolutionary technology look set to change the landscape significantly.

    Consolidation vs specialist providers in a growing market
    The demand for contract research organization (CRO)-conducted clinical trials has been and will continue to rise in 2019. In 2016, the overall bio/pharmaceutical outsourced development spend was $26 billion and is expected to reach $31 billion in 2019, while the market for CRO-conducted clinical development in 2015 was $25.7 billion and is expected to increase to $36.7 billion by 2020.

    This trend is being driven by the increased outsourced clinical activities to CROs in response to the ever-increasing size, complexity, duration and cost of clinical trials.

    Intense competition in this growing market has led CROs to seek advantages wherever they can and consolidation has been the only answer for some as they look to build a more comprehensive portfolio of service offerings. While consolidation may serve a purpose, it has several drawbacks: less competition and less choice for sponsors forces them to work with organizations that may offer the scale but not the in-depth knowledge or focused services available elsewhere with niche providers. In 2019, we’ll see a clear divide emerge between generic ‘one-size-fits-all’ solutions and more client-centric service providers.

    Data quality oversight
    As the pharmaceutical industry embraces new technologies and innovations, including electronic record keeping, the volume of information collected before, during and after clinical trials continues to grow. Similar to the adoption of electronic data capture (EDC) systems, which initially started slow and now is the norm, it could be expected that the same will occur with data quality oversight (DQO) once monitoring efforts are centralized.

    Data quality oversight (DQO) involves running statistical analytics and generating reports via CSM to identify outliers and anomalies and improve the quality and integrity of clinical trial data. Monitoring and clinical data management teams can then investigate and resolve these identified potential issues.

    In the ICH GCP E6 (R2) addendum the FDA accepted that pharmaceutical companies and their sponsors are under pressure to bring cost efficiencies to their processes. The Addendum gave the green light for new technologies and approaches to monitoring and oversight. It allows for a degree of source data verification (SDV) to no longer have to be done on site, as well as to reduce SDV from 100% where risk permits. This resulted in the acceptable use of risk based monitoring (RBM). The use of RBM has risen over recent years—research has shown that between 2009 and 2013, RBM adoption has risen from 33% to over 50% among industry stakeholders. It also resulted in remote monitoring and centralized statistical monitoring (CSM), which in turn leads to greater importance and value for improved data integrity and data oversight.

    Performing DQO during study conduct and improving data integrity—the maintenance of, and the assurance of the accuracy and consistency of, data over its entire life-cycle—leads to improved data quality in the final submission data used to demonstrate an investigational new drug’s (INDs) efficacy and safety. For example, a sponsor is now able to respond to any on-site issues faster by verifying source data remotely. Large trials with multiple centers and manual on-site monitoring via investigators are more time consuming from a cost and clinical research associate (CRA) perspective. It is in the best interest of sponsors to detect such potential issues before regulatory submissions and should see more companies adopting the approach in 2019.

    Pharmacovigilance
    It is expected that the pharmacovigilance (PV) market will register 10% growth to touch $8 billion by 2024, which makes it an exciting time to be a niche pharmacovigilance service provider. An increasingly comprehensive and complex regulatory framework, investment in exploiting scientific advances made in areas such as oncology, and the emergence of new novel therapies and technologies for rare diseases or other unmet medical needs, overall has led to more demand for specialist support in PV and risk management.

    2012 saw the introduction of good pharmacovigilance practices (GVPs) in the European Union (EU) and since then, the industry has experienced a huge amount of change, including the launches of the:
    • Medical Literature Monitoring (MLM) service;
    • Periodic Safety Update Report (PSUR) repository;
    • Extended EudraVigilance Medicinal Product Database (XEVMPD); and
    • New EudraVigilance system supporting centralized reporting and ISO-ICSR ICH E2B(R3) format submission and download.
    The industry has also seen changes to the Risk Management Plan (RMP), the introduction of PV fees, and stakeholder access to the EudraVigilance Data Analysis System (EVDAS) to support signal detection and assessment activities which remains in its pilot phase.

    The developments around EudraVigilance will be followed closely in 2019 by the pharma industry as it seeks to ensure that its new processes meet its requirements.

    Brexit
    One of the key considerations for the pharma industry when it comes to Brexit is pharmacovigilance (PV). The current situation is that, from 30 March 2019, EU PV activities will no longer be able to be conducted in the UK and vice versa.

    There is very little time to prepare for what the pharmaceutical industry will look like post-Brexit and it is likely that it will affect companies and sponsors at a wider business level. As we move forward it is vital that the industry carefully monitors output from the EMA and UK government to guide their strategy.

    The concerns surrounding Brexit and its impact on the industry mean that it will be all too easy for companies to take their eye off the ball when it comes to ensuring they meet the new PV regulations. It’s vital to ensure the necessary changes are made.

    What that means regarding the licensing of medicines and alignment/cooperation on a range of PV factors is still unknown. Clarification on the following EU-led initiatives will need to be considered in the negotiations between the EU and UK:
    • EudraVigilance;
    • The use of single assessment for Periodic Safety Update Reports (PSURs) and Risk Management Plans (RMPs); and
    • The role of the Pharmacovigilance Risk Assessment Committee (PRAC) and Qualified Person Responsible for Pharmacovigilance (QPPV).
    It is almost certain that after Brexit, marketing authorization holders (MAHs) will have to put in place a UK-based QPPV, as well as a EU QPPV based in the remaining EEA region to continue distributing drug products in both markets, although draft legislation issued by the UK government indicates that there may be a transitionary period of 21 months for establishing a UK QPPV, even in the event of a no-deal Brexit. Specialist PV providers in the respective regions are likely to be heavily relied upon in the coming years to ease the burden on pharma companies.

    Machine learning and artificial intelligence
    Artificial intelligence (AI) and machine learning (ML) is generating a lot of interest in the pharmaceutical industry at the moment with AI in drug discovery companies emerging. From a drug development and clinical data perspective however, it seems AI and ML could just be a fancy term for automation with few ‘real’ AI solutions in place.

    At industry events such as PhUSE conferences, both pharmaceutical and clinical research organizations (CROs) are currently working to facilitate AI solutions and working parties have been formed for joint collaboration. AI and ML has the potential to bring increased efficiencies to the statistical analysis and programming of clinical data and with the increasing costs of drug development, it’s easy to understand the appeal for pharmaceutical companies to create such solutions. However it seems only a handful of Pharma companies are championing this while others are trying to get up to speed. As a data focused CRO, Quanticate is developing some AI solutions that are more than automation and advanced programming, such as tools to make intelligence decisions based on historical data, another to help compare outputs across different datasets, and finally an AI based approach for knowledge sharing and training.

    With advances in technology in this AI space, and Pharma companies increasingly expecting service providers to have solutions in development, AI is expected to be “table stakes” in the industry by 2020.

    More orphan drugs
    There are estimated to be around 7,000 known distinct rare diseases that affect 350 million people worldwide, and approximately 80% of those rare diseases are caused by faulty genes. Scientific advances such as the CRISPR/Cas9 genome-engineering system have simplified the pharmaceutical and biotech industry’s ability to develop gene therapies, especially for single gene mutation disorders. The FDA now has more than 700 active Investigation New Drugs (INDs) for gene and cell therapies, and in 2017, approved two cell-based gene therapies (chimeric antigen receptor T-cells [CAR-T]) as well as the first gene-therapy product to be administered in vivo. Collins and Gottlieb, of the NIH and FDA respectively, have stated that, “it seems reasonable to envision a day when gene therapy will be a mainstay of treatment for many diseases.”

    Not only is there the satisfaction of being behind a ‘miracle cure’ and the varied and interesting and challenging science behind the rare disease trials, there are also financial incentives for pharmaceutical companies to step into this area. The U.S. Orphan Drug Act EU Regulation on Orphan Medicinal Products facilitate tax incentives, enhanced patent protection, and marketing rights and clinical research subsidies for companies developing orphan therapies.

    Orphan drugs then may help companies reduce the impact of revenue loss caused by patent expirations of blockbuster drugs as the incentives to help them with the development of rare diseases.
    Once successfully authorized, a rare disease drug can be purchased for a considerable amount, and research shows firms with marketed orphan drugs are more profitable than those without. It is fair to predict that more and more pharma companies will start working in the area of rare diseases and CROs will do well to have a good understanding and area of expertise in this field. 


    David Hukin is managing director at QVigilance. He has 15 years’ experience in the pharmaceutical industry, with more than 14 years working in the pharmacovigilance sector. David has worked in small, medium-sized and large specialty pharma/biotech companies and has gained pre- and post-marketing experience in a range of therapeutic areas including gastroenterology, hepatology, neurology, oncology and psychiatric conditions as well as advanced therapy medicinal products (ATMPs) and orphan drug indication products for rare diseases. Since 2015, David has worked in the specialist pharmacovigilance service provider sector, leading multiple large teams responsible for clinical and post-marketing for customers ranging from small pharma/biotech to large specialty and generic companies.

    Thomas Underwood is marketing manager at Quanticate where he has over 10 years’ experience. Originally working in operations in both clinical data management and programming, Thomas moved into the organization’s commercial division and has been in his current role for over eight years. An integral part of Thomas’s role is product development which has involved extensive research into industry regulations and the resulting technology and services these influence such as Risk Based Monitoring, Data Quality Oversight and Centralized Statistical Monitoring.
    Related Searches
    • quality
    • in vivo
    • outsourced
    • automation
    Suggested For You
    Trial Runners Trial Runners
    Mogene Mogene
    SGS Life Sciences SGS Life Sciences
    Implementing AI in Drug Discovery Implementing AI in Drug Discovery
    Quanticate Appoints SVP of Project Delivery Quanticate Appoints SVP of Project Delivery
    Leveraging AI to Advance Discovery, Development and Delivery Leveraging AI to Advance Discovery, Development and Delivery
    ICON Launches Drug Safety Reporting Solution ICON Launches Drug Safety Reporting Solution
    AI in Pharma: Transforming Data into Drugs AI in Pharma: Transforming Data into Drugs
    Wasdell Granted HPRA for New HQ Wasdell Granted HPRA for New HQ
    Quanticate Launches QVigilance Quanticate Launches QVigilance
    InveniAI, Kyowa Hakko Kirin Partner for Drug Discovery InveniAI, Kyowa Hakko Kirin Partner for Drug Discovery
    Merck KGaA, Cyclica in AI Screening Platform Pact Merck KGaA, Cyclica in AI Screening Platform Pact
    Three Ways Quality Can Impact a Business’s Bottom Line Three Ways Quality Can Impact a Business’s Bottom Line
    AI in Pharma: Transforming Data into Drugs AI in Pharma: Transforming Data into Drugs
    Cobra Biologics, Pall, Cell and Gene Therapy in Continuous Mfg. Tie-up  Cobra Biologics, Pall, Cell and Gene Therapy in Continuous Mfg. Tie-up

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • A New Era Of Vaccine And Biologic Drug Development
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    P&G, L'Oréal & Amorepacific Make News at CES
    Three Form Vertical Beauty Alliance
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login